ClinicalTrials.gg
RecruitingNCT07554326R&TUpdated Nov 18, 2026

Rise & Thrive: Community-Engagement Intervention for Stress and Depression in Youth.

An interventional study of Rise Together: Community Engagement Intervention and Adulting 101: Life Skills in Depressive Symptoms, Allostatic Load and Metabolic Syndrome, sponsored by Seattle Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 15 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Seattle Children's Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 18, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
15 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
559th of 3,322
300 · median 72
Started
2026
with 179 others
No phase
2,221 of 3,715
386 open now
Primary completion
2028-12
later than 573 of 714 live
Registered
3,612th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 559th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 180 that started in 2026, is one of 2,221 with no phase, reaches primary completion later than 573 of the 714 other live ones, and was the 3,612th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 15 Years to 20 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

American youth and young adults face persistent and chronic stressors, which have contributed to a mental health crisis in the United States. Four in 10 American high school students experience chronic feelings of sadness and hopelessness, 2 in 10 report suicidal ideation, and 1 in 10 attempt suicide. For adolescents and young adults, chronic stress translates to weathering, or wear and tear on the mind and body. Chronic stress in youth contributes to psychological distress, elevated allostatic load, and an elevated risk for chronic diseases and premature death. While the connection between chronic stress and health is well documented, few studies provide evidence on innovative, non-medication strategies to reduce stress and mitigate the consequences of chronic stress on psychological and physiological outcomes. Thus, there is a critical need to rigorously test interventions that prevent the negative influence of chronic stress on mental and physical health, beginning in adolescence. The specific aims of the study are to 1) Determine whether a community-engagement, peer-based behavioral intervention reduces depressive symptoms in adolescents and young adults, 2) Determine whether a community-engagement behavioral intervention lowers allostatic load scores in adolescents and young adults, and 3) Identify factors that help sustain or inhibit community-engagement and intervention effects for adolescents and young adults. To accomplish these aims, the team will conduct a phase II community-engaged, peer group-based, multi-component randomized behavioral clinical trial. We will collect psychological and physiological measures at baseline, then at 6-month intervals for 2 years post-community-engaged, skills training.

Read the detailed description

Detailed Description: The investigators will conduct a phase II group-based, multi-component, and multi-level randomized behavioral clinical trial. The investigators will recruit and enroll 300 participants aged 15-20 (N=150 intervention and N=150 control) in Chicago, Illinois. After enrollment, participants will be randomized using a block-stratified randomization technique to ensure balance regarding race, ethnicity, and gender. Once participants are recruited, the investigators will use a computer-generated random number sequence to assign participants to the intervention group (Rise Community Engagement) or control group (Adulting 101: Life Skills Training). Participants assigned to the intervention arm will participate in 5 half-day, peer-based, interactive sessions teaching community engagement principles. Participants will be assigned to the control arm and will participate in 5 half-day interactive sessions teaching life skills training. Participants in the control arm will undergo life skills training with the same number of sessions and duration as the intervention arm.

Participants in both the intervention and control arms will report depressive symptoms on a clinically relevant measure (e.g., Patient Health Questionnaire-9) at baseline and then \<1-, 6-, 12-, 18-, and 24- months post-initial 5-day community engagement or life skills training. In addition to depressive symptoms, the investigators will measure other aspects of psychological distress, including anxiety and stress, as secondary outcomes. Participants in both groups will have biometric samples, like blood draws, and clinical measurements of allostatic load at baseline and then 6-,12-, and 24- months post-initial 5-day community engagement or life skills training.

The proposed project will use a cluster randomized trial, which involves complete groups of individuals randomized to conditions (i.e., intervention, control), with clustering occurring in both arms. All of our statistical analyses will appropriately model the dependency among observations, which is a hallmark of multi-level modeling.

03

Conditions studied

  • Depressive Symptoms
  • Allostatic Load
  • Metabolic Syndrome

Keywords

  • mental health
  • youth intervention
  • allostatic load
  • stress
  • depressive symptoms
  • depression
  • metabolic syndrome
  • prevention
04

Who can participate

Ages eligible
15 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 15-20 years old
  2. Identify as Black and/ or Hispanic/Latine
  3. Speak English

Exclusion criteria

Exclusion Criteria:

  1. Younger than 15 years old, or older than 20 years old
  2. Unable to attend the in-person sessions
  3. Non-fluent English speaker
  4. Do not identify as Black or Hispanic/Latine
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Rise Together: Community Engagement Intervention Arm

    The "Rise Together" RJA intervention is a block stratified randomized, group behavioral intervention designed for Black and Latinx adolescents and young adults (AYAs). The curriculum will specifically focus on the principles of AYAs community engagement and problem-solving skills through peer relationships. Trained facilitators will lead both didactic and interactive sessions on 1) Community Building, 2) Unpacking Stress and Community Needs, 3) Creating SMART Goals, 4) Researching and Refining SMART Goals, 5) Building Your Team, 6) Story Sharing, and 7) Action Planning, focused on community needs and engagement. Participants will learn how to use sources to understand what the community needs (e.g., transportation, healthcare, and education). Participants will analyze policy, develop SMART goals, identify community leaders, and develop plans with peers. Additionally, Rise Together will foster a network of peer support and equip AYAs with community engagement knowledge.

    Behavioral: Rise Together: Community Engagement Intervention

  • Active comparator
    Adulting 101: Life Skills

    Adulting 101: Life Skills attention control is a 5-day in-person program that will meet the same number of sessions and duration as the experimental intervention. This attention control is based on the "Project Life" program, which was initially developed for individuals supporting youth transitioning out of foster care to teach life skills for independent living. This curriculum is delivered through didactic and interactive modules that provide knowledge and informational resources, along with hands-on activities and life skills demonstrations. Sessions include: 1) Community Building, 2) Career Preparation, 3) Education, 4)Money Management, 5) Health and Nutrition, 6) Home Management, and 7) Story Sharing. Participants will learn skills for adulthood and gain experience, developing career and education goals.

    Behavioral: Adulting 101: Life Skills

Interventions

  • BehavioralRise Together: Community Engagement Intervention

    The "Rise Together" RJA intervention is a block stratified randomized, group behavioral intervention designed for Black and Latinx adolescents and young adults (AYAs). The curriculum will specifically focus on the principles of AYAs community engagement and problem-solving skills through peer relationships. Trained facilitators will lead both didactic and interactive sessions on 1) Community Building, 2) Unpacking Stress and Community Needs, 3) Creating SMART Goals, 4) Researching and Refining SMART Goals, 5) Building Your Team, 6) Story Sharing, and 7) Action Planning, focused on community needs and engagement. Participants will learn how to use sources to understand what the community needs (e.g., transportation, healthcare, and education). Participants will analyze policy, develop SMART goals, identify community leaders, and develop plans with peers. Additionally, Rise Together will foster a network of peer support and equip AYAs with community engagement knowledge.

  • BehavioralAdulting 101: Life Skills

    Adulting 101: Life Skills attention control is a 5-day in-person program that will meet the same number of sessions and duration as the experimental intervention. This attention control is based on the "Project Life" program, which was initially developed for individuals supporting youth transitioning out of foster care to teach life skills for independent living. This curriculum is delivered through didactic and interactive modules that provide knowledge and informational resources, along with hands-on activities and life skills demonstrations. Sessions include: 1) Community Building, 2) Career Preparation, 3) Education, 4)Money Management, 5) Health and Nutrition, 6) Home Management, and 7) Story Sharing. Participants will learn skills for adulthood and gain experience, developing career and education goals.

06

What researchers measure

Primary outcomes

  1. Depressive Symptoms

    To evaluate depressive symptoms and overall depression, the investigators will use the following measurement tools: the Patient Questionnaire-9 \[PHQ-9\]. The investigators have chosen these metrics because these tools have been validated within our study population, and the PHQ-9 is used in clinical practice. The Patient Health Questionnaire-9 (PHQ-9) is used in clinical practice to diagnose and manage depression and has a minimal clinically important difference (MCID) of 5 points on the PHQ-9 total score. The minimum is a score of 0, and the maximum is a score of 27, with higher scores indicating worse depressive symptoms. The scoring is as follows: Scores 0-4: None/minimal depression, 5-9: mild depression, 10-14: moderate depression, 15-19: moderately severe depression, 20-27: severe depression.

    Time frame: Time Frame: at baseline and then 0-1-, 6-, 12-, 18-, and 24- months post initial 5-day intervention.

  2. Metabolic Syndrome

    Biomarkers will be collected from these systems: cardiovascular (e.g., systolic and diastolic blood pressure (measured in mmHg), serum triglycerides (mg/dL) and HDL cholesterol (mg/dL), metabolic (e.g., glycosylated hemoglobin \[HbA1c (mg/dL)\] , fasting glucose (mg/dL), waist circumference (cm), and insulin (U/ML). Will measure seated blood pressure, height (cm), weight (Kg), and waist circumference using the same protocols used in the HCHS/SOL Youth for rigor and reproducibility. To arrive at one reported value of metabolic syndrome, we will 1. a count of the number of signs that meet International Diabetes Federation (IDF) criteria, and 2. Also, create a continuous metabolic risk score. To calculate this score, each biomarker will have values standardized into a z-score, then sum the z-scores, (Before transformation waist circumference will be normed for age, sex, and race using nationally representative data from NHANES.)

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention

  3. Blood Pressure

    The investigators will measure systolic and diastolic blood pressure (measured in mmHg) using a size-appropriate blood pressure cuff.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  4. Triglycerides

    The investigators will measure serum triglycerides (mg/dL) as a component of lipid markers.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  5. High-density lipoprotein

    The investigators will measure HDL cholesterol (mg/dL) as a component of lipid markers.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  6. Glycosylated hemoglobin

    The investigators will measure HbA1c (mg/dL) as a marker of metabolic health.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  7. Glucose

    The investigators will measure fasting glucose (mg/dL) as a marker of metabolic health.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  8. Insulin

    The investigators will measure insulin (U/ML) as a marker of metabolic health.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  9. Waist Circumference

    The investigators will measure waist circumference (cm) as a marker of metabolic health.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

Secondary outcomes

  1. Perceived Stress

    The investigators will use the Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Short Form on psychological stress experiences to enhance rigor and reproducibility. This tool has acceptable reliability and validity in AYAs. The scoring range is 4-20, with higher scores indicating greater stress severity.

    Time frame: Time Frame: at baseline and then 0-1 month, 6-, 12-, 18-, and 24- months post initial 5-day intervention.

  2. Anxiety

    Anxiety will be measured using the Generalized Anxiety Disorder Questionnaire-7 (GAD-7). The GAD-7 has been validated with our study population and is used in clinical practice with an MCID of 4 points on the GAD-7 total score. The scoring is as follows: 0-4: Minimal anxiety, 5-9: Mild anxiety,10-14: Moderate anxiety, and 15-21: Severe anxiety.

    Time frame: Time Frame: at baseline and then 0-1 month, 6-, 12-, 18-, and 24- months post initial 5-day intervention.

  3. Inflammation

    The investigators will use biomarkers from inflammatory/immune systems (e.g., Hs-CRP (mg/L), IL-1β (pg/mL), IL-6 (pg/mL), IL-8 (pg/mL), suPAR (pg/mL), and TNF-α (pg/mL). The investigators plan to measure an inflammation score, by standardizing values each biomarker into a z-score, then sum the z-scores to arrive at one reported inflammation score.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  4. C-Reactive Protein

    The investigators will measure Hs-CRP (mg/L) as a measure of inflammation.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  5. Interleukin-1βeta

    The investigators will measure IL-1β (pg/mL) as a measure of inflammation.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention

  6. Interleukin-6

    The investigators will measure IL-6 (pg/mL) as a measure of inflammation.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  7. Interleukin-8

    The investigators will measure IL-8 (pg/mL) as a measure of inflammation.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  8. Soluble Urokinase Plasminogen Activator Receptor (suPAR)

    The investigators will measure suPAR (pg/mL) as a measure of inflammation.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

  9. Tumor Necrosis Factor alpha (TNF-α)

    The investigators will measure TNF-α (pg/mL) as a measure of inflammation.

    Time frame: Time Frame: at baseline and then 6-, 12-, and 24- months post initial 5 day-intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hope EC, Cryer-Coupet QR, Stokes MN. Race-related stress, racial identity, and activism among young Black men: A person-centered approach. Dev Psychol. 2020 Aug;56(8):1484-1495. doi: 10.1037/dev0000836. PubMed 32790447 ↗
  • Hope EC, Gugwor R, Riddick KN, Pender KN. Engaged Against the Machine: Institutional and Cultural Racial Discrimination and Racial Identity as Predictors of Activism Orientation among Black Youth. Am J Community Psychol. 2019 Mar;63(1-2):61-72. doi: 10.1002/ajcp.12303. Epub 2019 Jan 18. PubMed 30659621 ↗
  • Hope EC, Kornbluh M, Hagan M, Davis AL, Alexander A. Validation of the Black Community Activism Orientation Scale with racially and ethnically diverse college students. Am J Community Psychol. 2023 Mar;71(1-2):79-89. doi: 10.1002/ajcp.12633. Epub 2022 Nov 15. PubMed 36378747 ↗
  • Lewis TT, Cogburn CD, Williams DR. Self-reported experiences of discrimination and health: scientific advances, ongoing controversies, and emerging issues. Annu Rev Clin Psychol. 2015;11:407-40. doi: 10.1146/annurev-clinpsy-032814-112728. Epub 2015 Jan 2. PubMed 25581238 ↗
  • Lockwood KG, Marsland AL, Matthews KA, Gianaros PJ. Perceived discrimination and cardiovascular health disparities: a multisystem review and health neuroscience perspective. Ann N Y Acad Sci. 2018 Sep;1428(1):170-207. doi: 10.1111/nyas.13939. Epub 2018 Aug 8. PubMed 30088665 ↗
  • Ong AD, Williams DR, Nwizu U, Gruenewald TL. Everyday unfair treatment and multisystem biological dysregulation in African American adults. Cultur Divers Ethnic Minor Psychol. 2017 Jan;23(1):27-35. doi: 10.1037/cdp0000087. PubMed 28045308 ↗
  • Paradies Y, Ben J, Denson N, Elias A, Priest N, Pieterse A, Gupta A, Kelaher M, Gee G. Racism as a Determinant of Health: A Systematic Review and Meta-Analysis. PLoS One. 2015 Sep 23;10(9):e0138511. doi: 10.1371/journal.pone.0138511. eCollection 2015. PubMed 26398658 ↗
  • Alegria M, Shrout PE, Canino G, Alvarez K, Wang Y, Bird H, Markle SL, Ramos-Olazagasti M, Rivera DV, Cook BL, Musa GJ, Falgas-Bague I, NeMoyer A, Dominique G, Duarte C. The effect of minority status and social context on the development of depression and anxiety: a longitudinal study of Puerto Rican descent youth. World Psychiatry. 2019 Oct;18(3):298-307. doi: 10.1002/wps.20671. PubMed 31496076 ↗
  • Turan B, Foltz C, Cavanagh JF, Wallace BA, Cullen M, Rosenberg EL, Jennings PA, Ekman P, Kemeny ME. Anticipatory sensitization to repeated stressors: the role of initial cortisol reactivity and meditation/emotion skills training. Psychoneuroendocrinology. 2015 Feb;52:229-38. doi: 10.1016/j.psyneuen.2014.11.014. Epub 2014 Nov 22. PubMed 25497480 ↗
  • Hicken MT, Lee H, Ailshire J, Burgard SA, Williams DR. "Every shut eye, ain't sleep": The role of racism-related vigilance in racial/ethnic disparities in sleep difficulty. Race Soc Probl. 2013 Jun 1;5(2):100-112. doi: 10.1007/s12552-013-9095-9. PubMed 23894254 ↗
  • Adam EK, Heissel JA, Zeiders KH, Richeson JA, Ross EC, Ehrlich KB, Levy DJ, Kemeny M, Brodish AB, Malanchuk O, Peck SC, Fuller-Rowell TE, Eccles JS. Developmental histories of perceived racial discrimination and diurnal cortisol profiles in adulthood: A 20-year prospective study. Psychoneuroendocrinology. 2015 Dec;62:279-91. doi: 10.1016/j.psyneuen.2015.08.018. Epub 2015 Aug 28. PubMed 26352481 ↗
  • Chae DH, Nuru-Jeter AM, Adler NE, Brody GH, Lin J, Blackburn EH, Epel ES. Discrimination, racial bias, and telomere length in African-American men. Am J Prev Med. 2014 Feb;46(2):103-11. doi: 10.1016/j.amepre.2013.10.020. PubMed 24439343 ↗
  • Hill LK, Hoggard LS, Richmond AS, Gray DL, Williams DP, Thayer JF. Examining the association between perceived discrimination and heart rate variability in African Americans. Cultur Divers Ethnic Minor Psychol. 2017 Jan;23(1):5-14. doi: 10.1037/cdp0000076. PubMed 28045306 ↗
  • Lee DB, Peckins MK, Heinze JE, Miller AL, Assari S, Zimmerman MA. Psychological pathways from racial discrimination to cortisol in African American males and females. J Behav Med. 2018 Apr;41(2):208-220. doi: 10.1007/s10865-017-9887-2. Epub 2017 Sep 23. PubMed 28942527 ↗
  • Banales J, Aldana A, Richards-Schuster K, Flanagan CA, Diemer MA, Rowley SJ. Youth anti-racism action: Contributions of youth perceptions of school racial messages and critical consciousness. J Community Psychol. 2021 Nov;49(8):3079-3100. doi: 10.1002/jcop.22266. Epub 2019 Nov 6. PubMed 31691984 ↗
  • Hope EC, Velez G, Offidani-Bertrand C, Keels M, Durkee MI. Political activism and mental health among Black and Latinx college students. Cultur Divers Ethnic Minor Psychol. 2018 Jan;24(1):26-39. doi: 10.1037/cdp0000144. Epub 2017 Jun 26. PubMed 28650179 ↗
  • Heard-Garris N, Ekwueme PO, Gilpin S, Sacotte KA, Perez-Cardona L, Wong M, Cohen A. Adolescents' Experiences, Emotions, and Coping Strategies Associated With Exposure to Media-Based Vicarious Racism. JAMA Netw Open. 2021 Jun 1;4(6):e2113522. doi: 10.1001/jamanetworkopen.2021.13522. PubMed 34129023 ↗
  • Ballard PJ, Syme SL. Engaging youth in communities: a framework for promoting adolescent and community health. J Epidemiol Community Health. 2016 Feb;70(2):202-6. doi: 10.1136/jech-2015-206110. Epub 2015 Oct 6. PubMed 26443541 ↗
  • Cohen A, Ekwueme PO, Sacotte KA, Bajwa L, Gilpin S, Heard-Garris N. "Melanincholy": A Qualitative Exploration of Youth Media Use, Vicarious Racism, and Perceptions of Health. J Adolesc Health. 2021 Aug;69(2):288-293. doi: 10.1016/j.jadohealth.2020.12.128. Epub 2021 Feb 19. PubMed 33612361 ↗
  • Hope EC, Brinkman M, Hoggard LS, Stokes MN, Hatton V, Volpe VV, Elliot E. Black adolescents' anticipatory stress responses to multilevel racism: The role of racial identity. Am J Orthopsychiatry. 2021;91(4):487-498. doi: 10.1037/ort0000547. Epub 2021 Apr 22. PubMed 34338546 ↗
  • Volpe VV, Lee DB, Hoggard LS, Rahal D. Racial Discrimination and Acute Physiological Responses Among Black Young Adults: The Role of Racial Identity. J Adolesc Health. 2019 Feb;64(2):179-185. doi: 10.1016/j.jadohealth.2018.09.004. Epub 2018 Nov 6. PubMed 30409752 ↗
  • Gaydosh L, Schorpp KM, Chen E, Miller GE, Harris KM. College completion predicts lower depression but higher metabolic syndrome among disadvantaged minorities in young adulthood. Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):109-114. doi: 10.1073/pnas.1714616114. Epub 2017 Dec 18. PubMed 29255040 ↗
  • Volpe VV, Schorpp KM, Cacace SC, Benson GP, Banos NC. State- and Provider-Level Racism and Health Care in the U.S. Am J Prev Med. 2021 Sep;61(3):338-347. doi: 10.1016/j.amepre.2021.03.008. Epub 2021 Jun 24. PubMed 34419231 ↗
  • Pinedo A, Durkee MI, Diemer MA, Hope EC. Disentangling longitudinal trajectories of racial discrimination and critical action among Black and Latinx college students: What role do peers play? Cultur Divers Ethnic Minor Psychol. 2021 Jul;27(3):546-557. doi: 10.1037/cdp0000434. Epub 2021 Apr 29. PubMed 33914581 ↗

Individual participant data

Plan to share: Yes — Northwestern Univ. (NU) and Lurie Children's (LCH) are committed to the open and timely dissemination of all research outcomes through the development of repositories and databases, posting of data on open websites, presentations, and through publications as soon as is feasible after peer review. Team will assure the confidentiality of all human subjects' data and will adhere to all HIPAA rules to ensure compliance with human subject confidentiality requirements. Collaborators will ensure that any data obtained as a part of the awarded grant will be made available to collaborators and to the general research community through databases and public repositories and by publishing in printed or electronic form as soon as practically possible after the data have been obtained and peer-reviewed. Team agrees to publish all data derived from this award in a timely fashion and to make those data freely available via

Supporting information: Study protocol

Time frame: Research data will be made publicly available through posting on open websites, presentations, and peer-reviewed publications (in some cases after an embargo period not to exceed one year). Inventions appropriate for commercialization will be protected via intellectual property (IP) filings, commercialized, and provided to society as products or services by or through the Innovation and New Ventures Office, NU's technology transfer office. Innovation and New Ventures Office manages NU's invention disclosure, assessment, patenting, and marketing processes. NU is committed to the free exchange of data and resources and for the rapid commercialization of biomedical inventions for the benefit of the public, consistent with the terms of the Bayh-Dole Act. NU's commercialization practices to date have maximized the public benefit of inventions arising from federal funding by providing useful, commercially relevant, and available products and services.

Access criteria: Data and resource sharing is an essential to the study activities. The team will share the data and resources generated by this project by making our findings, intervention materials and protocols (e.g., training materials, manuals, etc.), available to the following communities: Scientists interested in developing, implementing, and testing activism as an approach to reduce the health risks associated with structural racism, particularly among adolescent and young adult populations. Data and resource sharing with this community will encourage dialogue about the nuances of activism as a youth health intervention, implementation, and evaluation research in youthfocused community settings. Practitioners, clinicians, youth educators, administrators, and other decision-makers, so our findings may be used to inform youth civic education and advocacy programming; The community at large, so adolescents, young adults, and their caregivers and educators can use our findings

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 29 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2028 → Dec 2029, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartActual
Jun 9, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 29, 2029was Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
1 site added — first site in United States
Show site
  • Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, United States
Oct 21, 2026
Start date
Changed, then back to Jun 9, 2026
moved 2 times, Oct 21, 2026 – Oct 22, 2026
Study completion
Dec 29, 2028→Dec 29, 2029
Oct 21, 2026
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago→Seattle Children's Hospital
Nov 18, 2026
Show all 3 updates
  1. Nov 18, 2026
    Sponsor Ann & Robert H Lurie Children's Hospital of Chicago→Seattle Children's Hospital
    + 2 other changes: identifiers and verification date
  2. Oct 22, 2026
    Start date May 25, 2026→Jun 9, 2026
  3. Oct 21, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, United States
    Start date Jun 9, 2026→May 25, 2026 (now actual)
    Study completion Dec 29, 2028→Dec 29, 2029
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07554326
Responsible party
Nia Heard-Garris (Principal Investigator, Seattle Children's Hospital) — Principal investigator
First posted
Apr 28, 2026
Start date
Jun 9, 2026
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 29, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Nia J Heard Garris, MD, MBA, MSc
Contact
nheardgarris@luriechildrens.org
3122272664
Akram Ibrahim, MS
Contact
akibrahim@luriechildrens.org
312-227-6944
Elan C Hope, PhD
principal investigator · Policy Research Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion